The Impacts of ERCC1 Gene Exon VIII Alternative Splicing on Cisplatin-Resistance in Ovarian Cancer Cells

被引：35

作者：

Sun, Yehong ^{[1
,2
]}

Li, Tiyuan ^{[2
]}

Ma, Kewei ^{[3
]}

Tian, Zhongkai ^{[2
]}

Zhu, Ying ^{[2
]}

Chen, Fuqiang ^{[2
]}

Hu, Gang ^{[1
]}

机构：

[1] Nanjing Med Univ, Dept Pharmacol, Nanjing 210029, Jiangsu, Peoples R China

[2] Jinan Univ, Shenzhen Clin Med Res Ctr, Med Coll 2, Shenzhen Peoples Hosp, Shenzhen 518020, Guangdong, Peoples R China

[3] Jilin Univ, Hosp 1, Dept Hemotol & Oncol, Changchun 130021, Peoples R China

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 09期

关键词：

ERCC1 exon VIII; Alternative splicing; DNA lesions repair; Drug resistance; Cisplatin; NUCLEOTIDE EXCISION-REPAIR; INDUCED DNA-DAMAGE; MOLECULAR-MECHANISMS; MISMATCH REPAIR; EXPRESSION; ENDONUCLEASE; LINES; XPA; CYTOTOXICITY; CHEMOTHERAPY;

D O I：

10.3109/07357900902744536

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Excision repair cross complementation group-1 (ERCC1) was reported to be responsible for drug resistance during cancer treatment. In this report, we first proved the existence of ERCC1 exon VIII alternative splicing in ovarian cancer cells. Further investigation showed that over-expressed exon VIII deficient ERCC1 variant failed to change the protein level of ERCC1 in cancer cells, but decreased the excision repair function of ERCC1 and enhanced sensitivity of cancer cells to cisplatin in a dose-dependent manner. The results indicate that ERCC1 exon VIII alternative splicing does exist in some ovarian cancer cell lines, and regulates cisplatin-resistance in ovarian cancer cells.

引用

页码：891 / 897

页数：7

共 32 条

[1]

Altaha R, 2004, INT J MOL MED, V14, P959

[2]

DIJT FJ, 1988, CANCER RES, V48, P6058

[3] Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells [J].

Ferry, KV ;

Fink, D ;

Johnson, SW ;

Nebel, S ;

Hamilton, TC ;

Howell, SB .

BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) :861-867

[4] Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells - Role of ERCC1-XPF [J].

Ferry, KV ;

Hamilton, TC ;

Johnson, SW .

BIOCHEMICAL PHARMACOLOGY, 2000, 60 (09) :1305-1313

[5] Current status of excision repair cross complementing-group 1 (ERCC1) in cancer [J].

Gossage, Lucy ;

Madhusudan, Srinivasan .

CANCER TREATMENT REVIEWS, 2007, 33 (06) :565-577

[6] RE-EXAMINATION AND FURTHER DEVELOPMENT OF A PRECISE AND RAPID DYE METHOD FOR MEASURING CELL-GROWTH CELL KILL [J].

HANSEN, MB ;

NIELSEN, SE ;

BERG, K .

JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 119 (02) :203-210

[7] Action of DNA repair endonuclease ERCC1/XPF in living cells [J].

Houtsmuller, AB ;

Rademakers, S ;

Nigg, AL ;

Hoogstraten, D ;

Hoeijmakers, JHJ ;

Vermeulen, W .

SCIENCE, 1999, 284 (5416) :958-961

[8] Molecular mechanisms involved in cisplatin cytotoxicity [J].

Jordan, P ;

Carmo-Fonseca, M .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (8-9) :1229-1235

[9] Mechanisms of resistance to cisplatin [J].

Kartalou, M ;

Essigmann, JM .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 478 (1-2) :23-43

[10]

Kiyohara Chikako, 2007, Int J Med Sci, V4, P59

← 1 2 3 4 →